Secondary Erythrocytosis Among Type 2 Diabetes Mellitus Patients With Hypogonadism Using Sodium‐Glucose Cotransporter 2 Inhibitors and Testosterone Replacement Therapy
Endocrinology, Diabetes & Metabolism · 2025
DOI: 10.1002/edm2.70064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2025. Verfasst von Maharan Kabha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Lady Davis Carmel Medical Center, Haifa, Israel. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Testosterone, Sodium-Glucose Transporter 2 Inhibitors, Polycythemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Hypogonadism is commonly linked to type 2 diabetes mellitus (T2DM), with testosterone replacement therapy (TRT) representing a key treatment option. Sodium glucose cotransporter‐2 inhibitors (SGLT‐2i) class is part of T2DM management. Both treatments can increase Hct, Hb and RBC levels with a potential risk for secondary erythrocytosis. This study compares Hct, RBC and Hb changes between T2DM patients treated with and without SGLT‐2i and TRT for hypogonadism.
Methods
Data from Clalit Healthcare Services (2015–2023) was analysed from male T2DM patients with hypogonadism. Mixed linear regression assessed SGLT‐2i effects on Hct, Hb and RBC levels, while generalised estimation equations were used to predict the proportion of patients with Hct > 54%.
Results
In total, 5235 male patients met the inclusion criteria, with 3146 in the SGLT‐2i (+) group, while 2089 comprised the SGLT‐2i (−) group. Mean age was 63.8 ± 11.0 years, mean Hct was 43.3% ± 4.4%, BMI was 30.8 ± 5.2 kg/m 2 and eGFR was 84.9 ± 19.3 mL/min/1.73m 2 . The SGLT‐2i (+) group demonstrated a statistically significant increase in Hct, Hb, and RBC after TRT initiation ( p < 0.001). While the overall increase in Hct > 54% was not statistically significant after TRT initiation with OR = 1.85 [95% CI 0.96–3.67], p = 0.06. However, in the SGLT2i (+) group, it was significantly higher than for those in the SGLT2i (−) group, OR = 4.85 [95% CI 3.06–7.69], p = 0.02.
Conclusions
SGLT‐2i and TRT co‐administration are associated with an increased chance of developing secondary erythrocytosis in T2DM. Awareness and potential treatment discontinuation may prevent unnecessary investigations. Frequent monitoring of these parameters is essential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Lady Davis Carmel Medical Center, Haifa, Israel.
- Ruth and Bruce Rappaport Faculty of Medicine, Technion-Institute of Technology, Haifa, Israel.
- Research Authority, Clalit Health Care Organization, Carmel Medical Center, Haifa, Israel.
- Department of Internal Medicine, Carmel Medical Center, Palai, Kerala, India.
- Division of Endocrinology and Metabolism, Clalit Medical Health Care Services, Haifa, Israel.
- The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
ORCID-Profile: Adnan Zaina
Zitieren
APA
Kabha, M., Dana, H., Kassem, S., Dekel, Y., Cohen, H., & Zaina, A. (2025). Secondary Erythrocytosis Among Type 2 Diabetes Mellitus Patients With Hypogonadism Using Sodium‐Glucose Cotransporter 2 Inhibitors and Testosterone Replacement Therapy. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70064
Vancouver
Kabha M, Dana H, Kassem S, Dekel Y, Cohen H, Zaina A. Secondary Erythrocytosis Among Type 2 Diabetes Mellitus Patients With Hypogonadism Using Sodium‐Glucose Cotransporter 2 Inhibitors and Testosterone Replacement Therapy. Endocrinology, Diabetes & Metabolism. 2025. doi:10.1002/edm2.70064
BibTeX
@article{Kabha2025,
author = {Kabha, Maharan and Dana, Hadar and Kassem, Sameer and Dekel, Yoram and Cohen, Hilla and Zaina, Adnan},
title = {Secondary Erythrocytosis Among Type 2 Diabetes Mellitus Patients With Hypogonadism Using Sodium‐Glucose Cotransporter 2 Inhibitors and Testosterone Replacement Therapy},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
doi = {10.1002/edm2.70064}
}
EUVIMED